Deutsche Bank Ag\ Bio Atla, Inc. Transaction History

Deutsche Bank Ag\

$212 Billion
Q1 2024

A detailed history of Deutsche Bank Ag\ transactions in Bio Atla, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 1,244,247 shares of BCAB stock, worth $1.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,244,247

Previous 1,125,203 10.58%

Holding current value

$1.7 Million

Previous $2.77 Million 54.68%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.88 - $3.46 $223,802 - $411,892	119,044 Added 10.58%	1,244,247 $4.28 Million
Q4 2023 Feb 14, 2024	BUY	$1.27 - $3.18 $1.07 Million - $2.69 Million	846,081 Added 303.12%	1,125,203 $2.77 Million
Q3 2023 Nov 09, 2023	SELL	$1.7 - $3.07 $702,555 - $1.27 Million	-413,268 Reduced 59.69%	279,122 $474,000
Q1 2023 May 15, 2023	BUY	$2.3 - $8.25 $675,673 - $2.42 Million	293,771 Added 73.7%	692,390 $1.86 Million
Q4 2022 Feb 13, 2023	BUY	$7.63 - $11.01 $763,000 - $1.1 Million	100,000 Added 33.49%	398,619 $3.29 Million

Q3 2022 Nov 14, 2022	BUY	$2.94 - $11.87 $441,000 - $1.78 Million	150,000 Added 100.93%	298,619 $2.3 Million
Q2 2022 Aug 11, 2022	SELL	$2.13 - $5.38 $70,157 - $177,206	-32,938 Reduced 18.14%	148,619 $424,000
Q1 2022 May 13, 2022	SELL	$4.38 - $18.78 $4,051 - $17,371	-925 Reduced 0.51%	181,557 $908,000
Q4 2021 Feb 11, 2022	SELL	$19.0 - $30.95 $41,021 - $66,821	-2,159 Reduced 1.17%	182,482 $3.58 Million
Q3 2021 Nov 04, 2021	SELL	$29.44 - $43.74 $5.53 Million - $8.22 Million	-187,970 Reduced 50.45%	184,641 $5.44 Million
Q2 2021 Aug 11, 2021	BUY	$38.07 - $56.17 $13.9 Million - $20.5 Million	364,924 Added 4747.29%	372,611 $15.8 Million
Q1 2021 May 13, 2021	BUY	$32.41 - $70.91 $249,135 - $545,085	7,687 New	7,687 $0

Others Institutions Holding BCAB

# of Institutions

Shares Held

24.8M

Call Options Held

140K

Put Options Held

4.6K

View Full List

About BioAtla, Inc.

Ticker BCAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,304,100
Market Cap $49.7M
Description
BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...

More about BCAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account